Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Open-label Phase Ib Study of RNActive®-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor

NCT01915524 is registered in ClinicalTrials.gov with CureVac as lead sponsor.

NCT NCT01915524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01915524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Open-label Phase Ib Study of RNActive®-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor
Lead sponsor
CureVac
Phase
Phase 1
Overall status
Terminated
Start date
April 30, 2013
Completion date
July 31, 2016
Enrollment
26 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung carcinoma